12 related news articles for Metastasis Biology and Therapeutics

  • Spotlight: supporting ovarian cancer research

    There are few parts of the Australian community that remain untouched by ovarian cancer. The team at Spotlight Group Holdings, one of the nation’s largest retail organisations, is supporting Hudson Institute’s work to help find a cure and better early diagnostics for the deadly disease.…  Read more

    Spotlight Morry Fraid, Ben Clark, Dr Maree Bilandzic
  • Jessica’s story, ovarian cancer at a young age

    Jessica Clark calls herself the luckiest unlucky person in the world – but she still wants to know why she got ovarian cancer at such a young age.…  Read more

    Jessica Clark, Ovarian Cancer Survivor, at home with husband Ben and daughter Matilda
  • CUREator funds Hudson Institute biotech innovation

    Exciting new treatments for unmet medical needs including ovarian cancer have been awarded significant funding from Australia’s national biotechnology incubator, CUREator.…  Read more

    Dr Andrew Stephens, Dr Maree Bilandzic, Adjunct Associate Professor Rebecca Lim at Hudson Institute
  • Researchers frock up for Frocktober

    For the month of ‘frocktober’ ovarian cancer researchers, Dr Maree Bilandzic and Dr Amy Wilson swapped their white lab coats for colourful frocks as part of the Frocktober campaign to raise funds and awareness for ovarian cancer research.…  Read more

    Scientists, Dr Amy Wilson and Dr Maree Bilandzic all dressed up in the lab in stunning dresses, supporting OCRF Frocktober
  • Ovarian cancer ‘invasion cells’ identified

    Highly mobile, invasive ovarian cancer cells called ‘leader cells’ have been discovered as the cells that lead the attack on healthy tissue.…  Read more

    Dr Maree Bilandzic from the Ovarian Cancer Biomarkers Research Group at Hudson Institute investigates the deadliest ovarian cancer cells
  • Funding to combat deadly ovarian cancer

    Dr Bilandzic, an ovarian cancer researcher, has been awarded $700,000 for research into deadly ovarian cancer cells called ‘leader cells’, which can survive and even thrive in response to cancer treatment. …  Read more

    Dr Maree Bilandzic from the Ovarian Cancer Biomarkers Research Group at Hudson Institute investigates the deadliest ovarian cancer cells
  • 2019 IMPACT Philanthropy – Perpetual

    Two Hudson Institute researchers, Dr Jun Yang and Dr Maree Bilandzic have been successful in the 2019 IMPACT Philanthropy program, from Perpetual, which are awarded to organisations based on their strategy, outcomes, capability and leaderships.…  Read more

    Dr Maree Bilandzic and Dr Jun Yang at Hudson Institute of Medical Research
  • 2019 Hudson Institute Travel Awards and Bryan Williams Trainee Scholarship

    Congratulations to the 2019 Hudson Institute Travel Awards recipients who will attend international conferences and visit laboratories to build invaluable knowledge in their area of research.…  Read more

    We'd like to offer our congratulations to the 2019 Hudson Institute Travel Awards and Bryan Williams Trainee Scholarship winners.
  • Fighting ovarian cancer at the front line

    Ovarian cancer is responsible for more deaths than any other gynaecological disease, yet it’s known as the ‘silent killer’, due to an absence of symptoms and a devastatingly low survival rate of less than 50 per cent. Our leading ovarian cancer researchers are progressing solutions to help these women – thanks to support from the…  Read more

    Dr Maree Bilandzic from the Ovarian Cancer Biomarkers Research Group at Hudson Institute - White Shirt Campaign
  • Ovarian Cancer Research Symposium

    Ovarian cancer research leaders from across Australia met at Hudson Institute of Medical Research on Thursday, 15 November, for a new research symposium focused on progressing solutions to the disease.…  Read more

    The Ovarian Cancer Research Foundation (OCRF) hosted the inaugural Ovarian Cancer Research Symposium at Hudson Institute..
  • Towards an early detection test for ovarian cancer

    The Active Ratio Test represents an exciting step forward in innovative ovarian cancer research. Should it be successful, a test as simple as taking a swab or blood sample will result in the early detection of ovarian cancer in women who otherwise exhibit no symptoms. Vague and misleading symptoms, combined with the need for invasive…  Read more

    Dr Maree Bilandzic from the Ovarian Cancer Biomarkers Research Group at Hudson Institute
  • 2018 Fielding Foundation Fellowship and Innovation Award announced

    Hudson Institute’s brightest scientific minds and most promising discoveries will be progressed, thanks to support from a leading philanthropist, Mr Peter Fielding and the Fielding Foundation. The 2018 Fielding Innovation Award has been awarded to Dr Maree Bilandzic to develop more effective treatments for women with ovarian cancer. The 2018 Fielding Foundation Fellowship has been…  Read more